Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Eftilagimod Alpha

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immutep Combo Hits Endpoint in Ph2 Sarcoma Study
    Immutep Combo Hits Endpoint in Ph2 Sarcoma Study

    27 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/27/3088523/0/en/Immutep-s-Efti-with-Radiotherapy-KEYTRUDA-pembrolizumab-Meets-Primary-Endpoint-in-Phase-II-for-Soft-Tissue-Sarcoma.html

    GLOBENEWSWIRE
    27 May 2025
    Share Share
    Immutep’s efti with PD-L1 achieves high response in lung cancer
    Immutep’s efti with PD-L1 achieves high response in lung cancer

    16 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/15/3082100/0/en/Immutep-s-Efti-with-KEYTRUDA-pembrolizumab-Chemotherapy-Achieves-High-Response-Rates-in-First-Line-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    16 May 2025
    Share Share
    Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design
    Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design

    22 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/22/2916491/0/en/Immutep-Announces-Successful-Meeting-with-FDA-on-Phase-III-Design-in-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    22 Jul 2024
    Share Share
    Immutep Reports Positive Results In First Line Head And Neck Cancer
    Immutep Reports Positive Results In First Line Head And Neck Cancer

    11 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/11/2912179/0/en/Immutep-Reports-Positive-Results-in-First-Line-Head-and-Neck-Squamous-Cell-Carcinoma-Patients-with-Negative-PD-L1-Expression.html

    GLOBENEWSWIRE
    11 Jul 2024
    Share Share
    Immutep To Present Clinical Results At ESMO Virtual Plenary And Host Webcast
    Immutep To Present Clinical Results At ESMO Virtual Plenary And Host Webcast

    03 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/03/2908114/0/en/Immutep-Announces-Details-for-Oral-Presentation-at-ESMO-Virtual-Plenary-Session-and-Webcast-to-Discuss-Clinical-Results.html

    GLOBENEWSWIRE
    03 Jul 2024
    Share Share
    Commercial Manufacturing of Eftilagimod at 2000L Scale Granted Authorization
    Commercial Manufacturing of Eftilagimod at 2000L Scale Granted Authorization

    21 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/21/2747207/0/en/Commercial-Manufacturing-of-Eftilagimod-Alpha-at-2000L-Scale-Granted-Authorization-for-Clinical-Trial-Use.html

    GLOBENEWSWIRE
    21 Sep 2023
    Share Share